Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Issue 8 (May 2015)

• Record Type: Journal Article
• Authors: Yoshida, M.; Muro, K.; Tsuji, A.; Hamamoto, Y.; Yoshino, T.; Yoshida, K.; Shirao, K.; Miyata, Y.; Takahari, D.; Takahashi, T.; Ohtsu, A.
• Is Part Of: European journal of cancer. Volume 51:Issue 8(2015:May)
• Page Start: 935
• Page End: 941
• Publication Date: 2015-05
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2015.03.007
• Languages: English
• ISSNs: 0959-8049

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab010"> <title id="st125">Abstract</title> <sec> <title id="st090">Background</title> <p id="sp0020">Chemotherapeutic regimens for elderly patients with metastatic colorectal cancer (mCRC), such as bevacizumab combined with 5-fluorouracil (5-FU) and leucovorin, often exclude oxaliplatin and irinotecan owing to the risk of toxicity. However, treatment with infusional 5-fluorouracil and leucovorin requires percutaneous port-catheter placement and other precautions, causing unnecessary stress for patients as well as healthcare workers.</p> </sec> <sec> <title id="st095">Methods</title> <p id="sp0025">We conducted a phase II study to evaluate the efficacy and safety of bevacizumab plus S-1 in elderly patients with previously untreated mCRC. Bevacizumab was given intravenously every two weeks, and S-1 was administered orally on days 1–28 of a 42-day cycle. The primary end-point was progression-free survival (PFS). The secondary end-points were time to treatment failure, response rate (RR), overall survival (OS), treatment completion status and safety.</p> </sec> <sec> <title id="st100">Results</title> <p id="sp0030">From October 2007 through March 2010, 56 patients were enroled. The median PFS was 9.9 months, the median OS was 25.0 months, and the RR was 57%. The main adverse events of grade 3 or higher were hypertension (11%), diarrhoea (9%) and neutropenia (7%).</p> </sec> <sec> <title id="st105">Conclusion</title> <p id="sp0035">Our results suggest that combination chemotherapy with S-1 and bevacizumab can be administered safely and continuously on an outpatient basis and is therapeutically effective in elderly patients with mCRC.</p> </sec> </abstract>